PIIANP and HELIXII diurnal variation

Osteoarthritis and Cartilage

Volumn 16, Issue 10, 2008, Pages 1192-1195

  Quintana, D J ^a   Garnero, P ^b,c   Huebner, J L ^a   Charni Ben Tabassi, N ^b   Kraus, V B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Molecular Markers   (France)

^c INSERM   (France)

Author keywords

Collagen II biomarker; Diurnal variation; Osteoarthritis

Indexed keywords

CHONDROITIN SULFATE; COLLAGEN; COLLAGEN TYPE 2; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOLLAGEN TYPE 2A AMINOPROPEPTIDE;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD INTAKE; HOSPITAL ADMISSION; HUMAN; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; MALE; NONPARAMETRIC TEST; PHYSICAL ACTIVITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; CIRCADIAN RHYTHM; COHORT STUDIES; COLLAGEN TYPE II; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; STATISTICS AS TOPIC;

EID: 51149117589     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.03.006     Document Type: Article

References (15)

1. Rousseau J.C., Zhu Y., Miossec P., Vignon E., Sandell L.J., Garnero P., et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 12 (2004) 440-447
2. Kraus V.B. Do biochemical markers have a role in osteoarthritis diagnosis and treatment?. Best Pract Res Clin Rheumatol 20 (2006) 69-80
3. Ryan M.C., and Sandell L.J. Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J Biol Chem 265 (1990) 10334-10339
4. Aigner T., Zhu Y., Chansky H.H., Matsen III F.A., Maloney W.J., and Sandell L.J. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 42 (1999) 1443-1450
5. Charni N., Juillet F., and Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 52 (2005) 1081-1090
6. Garnero P., Tabassi N.C., Juillet F., Whittles R.C., and Sharif M. A new serum-based assay for type II collagen helical peptide (serum HELIX-II) is associated with long-term radiological progression in knee osteoarthritis. Osteoarthritis Cartilage 15 (2007) C49-C50
7. Criscione L.G., Elliott A.L., Stabler T., Jordan J.M., Pieper C.F., and Kraus V.B. Variation of serum hyaluronan with activity in individuals with knee osteoarthritis. Osteoarthritis Cartilage 13 (2005) 837-840
8. Lindqvist U., Engstrom-Laurent A., Laurent U., Nyberg A., Bjorklund U., Eriksson H., et al. The diurnal variation of serum hyaluronan in health and disease. Scand J Clin Lab Investig 48 (1988) 765-770
9. Manicourt D.H., Poilvache P., Nzeusseu A., van Egeren A., Devogelaer J.P., Lenz M.E., et al. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum 42 (1999) 1861-1869
10. Gordon CD, Stabler TV, Kraus VB. Variation in osteoarthritis biomarkers from activity not food consumption. Clinica Chimica Acta, in press.
11. Kong S.Y., Stabler T.V., Criscione L.G., Elliott A.L., Jordan J.M., and Kraus V.B. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 54 (2006) 2496-2504
12. Kellgren J.H., and Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16 (1957) 494-502
13. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
14. Christgau S., Henrotin Y., Tanko L.B., Rovati L.C., Collette J., Bruyere O., et al. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 22 (2004) 36-42
15. Cibere J., Thorne A., Kopec J.A., Singer J., Canvin J., Robinson D.B., et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 32 (2005) 896-902